The Three Catecholics Benserazide, Catechol and Pyrogallol are GPR35 Agonists.
1Biochemical Technologies, Science and Technology Division, Corning Inc., Corning, NY 14831, USA. fangy2@corning.com.
Pharmaceuticals (Basel, Switzerland)
|November 27, 2013
Summary
Several catechol-containing drugs, known as catecholics, were found to activate the GPR35 receptor. This discovery opens new avenues for understanding drug interactions and developing targeted therapies.
Area of Science:
- Pharmacology
- Biochemistry
- Drug Discovery
Background:
- Catecholics represent approximately 1% of all clinically utilized medications.
- These compounds share a common catechol structural motif.
Purpose of the Study:
- To investigate the potential G protein-coupled receptor 35 (GPR35) agonistic activity of various catecholics.
- To identify specific catechol-containing compounds that interact with GPR35.
Main Methods:
- Utilized label-free dynamic mass redistribution (DMR) assays.
- Employed Tango β-arrestin translocation assays to assess receptor activation.
Main Results:
- Several catecholics demonstrated significant agonistic activity at the GPR35 receptor.
- Identified compounds include benserazide, catechol, 3-methoxycatechol, pyrogallol, (+)-taxifolin, and fenoldopam.
Conclusions:
- The findings reveal that a range of catecholics can act as agonists for GPR35.
- This interaction suggests a potential mechanism of action for these drugs and highlights GPR35 as a target for future drug development.
More Related Videos
Related Concept Videos
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.4K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
01:18Adrenergic Agonists: Therapeutic Classification
1.8K
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
1.8K
01:27Transducer Mechanism: Enzyme-Linked Receptors
4.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.4K
01:30Adrenergic Agonists: Direct-Acting Agents
2.8K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
2.8K
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
1.7K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.7K
01:26Adrenergic Receptors: β Subtype
3.8K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.8K